In terms of T2DM with SGLT-2 inhibitors, our results revealing neutral effects on newly diagnosed bladder cancer are compatible with those of a previous meta-analysis of large randomized controlled trials, which showed that SGLT-2 inhibitors had no significantly increased risks of bladder cancer [22]. This evidence concerns the gene SLC5A2 and urinary bladder carcinoma.